Cross-Sector entity
Of the tracked stories, 3 of 6 also mention Apogee Therapeutics, the most common co-covered peer. The 18-day window averages about 2.3 stories each week. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 2 of those 6, with the remainder spread across 3 other categories.
6 verified stories tracked
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 6 also mention Apogee Therapeutics, the most common co-covered peer. The 18-day window averages about 2.3 stories each week. The busiest single day carried 3. Coverage clusters in market-trends, which accounts for 2 of those 6, with the remainder spread across 3 other categories. Negative sentiment appears in 0% of the tracked stories. Arcturus Therapeutics appears in 6 tracked Cross-Sector stories published from March 2, 2026 through March 19, 2026. Each carries 2 original sources on average.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Arcturus Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Source: benzinga.com · benzinga.com
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
